Type 2 diabetes mellitus (T2DM) is a complex progressive metabolic derangement associated with comorbidities such as obesity, dyslipidemia, and hypertension. Although a wide range of pharmacotherapies is available for T2DM, determining management strategies for T2DM that balance effectiveness, safety, and tolerability remains complex and challenging.

The prevalence of T2DM has increased rapidly in Asia, including South Korea, over the past several decades \[[@B1]\]. The pathophysiologic mechanisms underlying T2DM in Asia are thought to be different from those in Western countries. In particular, pancreatic β-cell dysfunction may be important for the development of T2DM in certain Asian populations \[[@B2],[@B3]\].

Progressive β-cell failure, weight gain and hypoglycemia are the main side effects of sulfonylurea, one of the most commonly used antidiabetic agents. Long-term use of sulfonylurea can lead to the failure of monotherapy and ultimate dependence on insulin injections. Glucagon like peptide (GLP)-1 stimulates pancreatic β-cell differentiation and proliferation, and inhibits apoptosis \[[@B4]\]. Dipeptidyl peptide-4 (DPP-4) inhibitors enhance levels of active incretin hormones, gut-derived peptides that are released into the circulation after eating \[[@B5]\]. Sitagliptin is an oral, once-daily, potential, highly selective DPP-4 inhibitor. Numerous clinical studies of sitagliptin have been reported since the US Food and Drug Administration approved sitagliptin for monotherapy or combination therapy with metformin or thiazolidinedione in 2006 \[[@B5]-[@B9]\]. According to a systemic review and meta-analysis, DPP-4 inhibitors lowered HbA1C by 0.74% (95% confidence interval \[CI\], 0.62% to 0.85%) compared with placebo \[[@B10]\].

Most studies indicate that sitagliptin treatment leads to significant improvements in β-cell function. Given the important role that β-cell dysfunction plays in the progression of hyperglycemia, especially in Asian patients, sitagliptin treatment may be of particular therapeutic relevance for T2DM in Asian contexts. However, clinical studies of sitagliptin therapies in Asian or Korean diabetic patients are rare. A 2009 study found that 18 week sitagliptin monotherapy was associated with significantly improved glycemic control (mean HbA1c reduction, -1.0%) and was well tolerated by T2DM patients from China, India, and Korea \[[@B11]\]. According to this study, the reduction of HbA1C relative to placebo was greater in Korean and Indian patients than in Chinese patients. The mean (95% CI) reductions in HbA1C with sitagliptin treatment were -1.4% (-1.9% to -0.8%) in Korean patients, -1.4% (-1.7% to -1.0%) in Indian patients, and -0.7% (-0.9% to -0.5%) in Chinese patients. Furthermore, Korean patients showed the greatest reductions of fasting glucose and 2-hour postprandial glucose levels. However, the reasons for these differences were not elucidated, although the authors suggested regional differences in environment, genetics, or adherence to study co-interventions such as diet and exercise.

Due to the current insufficiency of Asian or Korean data regarding sitagliptin efficacy in patients with T2DM, the study by Kim et al. \[[@B12]\] is particularly relevant. In that study, younger, thinner diabetic patients were observed to have better therapeutic results than older, heavier patients, suggesting that BMI and age should be considered before the selection of sitagliptin or other DPP-4 inhibitors for use in diabetic therapies. Treatment response was defined as \>10% HbA1c reduction or \>20% fasting glucose reduction, and by this definition, the frequency of response in their sample was 81%. As many previous clinical studies defined successful glucose-lowering effects according to the number of patients with HbA1c \<7%, additional studies are necessary to assess the therapeutic effects of sitagliptin and to identify clinical characteristics of patients that predict sitagliptin response.
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